Emergent BioSolutions Inc. presented preclinical data on its lead bispecific Adaptir therapeutic, ES414, at the 5th Annual Protein and Antibody Engineering Summit (PEGS) in Lisbon, Portugal. The ES414 molecule was constructed using Emergent’s Adaptir technology platform and is being developed as a potential therapeutic for metastatic castration-resistant prostate cancer (mCRPC).
The presentation shared results of preclinical studies demonstrating ES414 is pharmacologically active and well tolerated. Preclinical in vitro and in vivo studies have shown ES414 redirects T-cell cytotoxicity (RTCC) towards prostate cancer cells expressing prostate specific membrane antigen (PSMA), an antigen commonly found on prostate cancer cells. The ES414 molecule selectively binds and links the T cell receptor on cytotoxic T cells to the PSMA on tumor cells, triggering tumor cell destruction.